INVO BIOSCIENCE INC (INVO) Stock Price, Quote, News and Overview
NASDAQ:INVO - Nasdaq - US44984F4019 - Common Stock - Currency: USD
INVO Quote, Performance and Key Statistics
0.833
-0.03 (-2.91%)
The current stock price of INVO is 0.833 USD. In the past month the price increased by 20.13%. In the past year, price decreased by -35.92%.
INVO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About INVO
Company Profile
INVO BioScience, Inc. is a fertility company. The company is headquartered in Lakewood Ranch, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The firm is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The firm operates three INVO Centers in North America.
Company Info
INVO BIOSCIENCE INC
5582 Broadcast Ct
Lakewood Ranch FLORIDA 34240 US
CEO: Steven Shum
Employees: 25
Company Website: https://invobioscience.com/
Phone: 19788789505
INVO BIOSCIENCE INC / INVO FAQ
What is the stock price of INVO BIOSCIENCE INC today?
The current stock price of INVO is 0.833 USD. The price decreased by -2.91% in the last trading session.
What is the ticker symbol for INVO BIOSCIENCE INC stock?
The exchange symbol of INVO BIOSCIENCE INC is INVO and it is listed on the Nasdaq exchange.
On which exchange is INVO stock listed?
INVO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INVO BIOSCIENCE INC stock?
6 analysts have analysed INVO and the average price target is 20.4 USD. This implies a price increase of 2348.98% is expected in the next year compared to the current price of 0.833. Check the INVO BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INVO BIOSCIENCE INC worth?
INVO BIOSCIENCE INC (INVO) has a market capitalization of 3.26M USD. This makes INVO a Nano Cap stock.
How many employees does INVO BIOSCIENCE INC have?
INVO BIOSCIENCE INC (INVO) currently has 25 employees.
What are the support and resistance levels for INVO BIOSCIENCE INC (INVO) stock?
INVO BIOSCIENCE INC (INVO) has a support level at 0.78 and a resistance level at 0.86. Check the full technical report for a detailed analysis of INVO support and resistance levels.
Is INVO BIOSCIENCE INC (INVO) expected to grow?
The Revenue of INVO BIOSCIENCE INC (INVO) is expected to grow by 199.65% in the next year. Check the estimates tab for more information on the INVO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INVO BIOSCIENCE INC (INVO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INVO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INVO, evaluating the profitability, health, valuation and growth aspects
- INVO BIOSCIENCE INC (INVO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INVO BIOSCIENCE INC (INVO) Sales and EPS estimates to see what analysts future expectations are.
- INVO BIOSCIENCE INC (INVO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INVO BIOSCIENCE INC (INVO) Insider and Institutional Ownership to learn about the owners and their transactions.
- INVO BIOSCIENCE INC (INVO) Stock Chart to make your own analysis
- INVO BIOSCIENCE INC (INVO) Latest news and press-releases to stay up to date.
Does INVO BIOSCIENCE INC (INVO) stock pay dividends?
INVO does not pay a dividend.
When does INVO BIOSCIENCE INC (INVO) report earnings?
INVO BIOSCIENCE INC (INVO) will report earnings on 2024-11-11, after the market close.
What is the Price/Earnings (PE) ratio of INVO BIOSCIENCE INC (INVO)?
INVO BIOSCIENCE INC (INVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.24).
INVO Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to INVO. When comparing the yearly performance of all stocks, INVO is a bad performer in the overall market: 85.67% of all stocks are doing better.
INVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INVO. Both the profitability and financial health of INVO have multiple concerns.
INVO Financial Highlights
Over the last trailing twelve months INVO reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS increased by 79.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.3% | ||
| ROE | -519.72% | ||
| Debt/Equity | 1.51 |
INVO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to INVO. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 50% and a revenue growth 199.65% for INVO